Christina Smolke

Christina Smolke is a bioengineer and synthetic biologist known for pioneering RNA-based regulatory systems and for engineering yeast to produce complex small molecules. Her work spans molecular biology, chemical synthesis, and biotechnology commercialization, connecting academic research with industrial translation. She has held faculty positions at Stanford University and founded companies to translate engineered biosynthesis platforms into pharmaceutical production.

Early life and education

Smolke completed undergraduate studies at Oregon State University where she studied chemistry and biology, then pursued graduate training at the Massachusetts Institute of Technology in laboratories that emphasized molecular engineering, biochemical synthesis, and computational design. During doctoral and postdoctoral periods she trained alongside researchers affiliated with institutions such as Harvard University, MIT Media Lab, and members of the Broad Institute network, developing expertise in RNA engineering, enzymology, and metabolic pathway assembly. Her formative mentors and collaborators included faculty from departments linked to Stanford University and national laboratories like Lawrence Berkeley National Laboratory, fostering interdisciplinary skills crossing molecular design, biotechnology translation, and systems biology.

Research and career

Smolke’s academic career includes a faculty appointment in bioengineering at Stanford University where she led a laboratory integrating principles from chemical engineering, biochemistry, and molecular biology to create programmable biological systems. Her group worked on RNA design, synthetic gene networks, and metabolic engineering for production of pharmaceuticals, collaborating with researchers at institutions such as University of California, Berkeley, California Institute of Technology, and international centers including Imperial College London and ETH Zurich. She has contributed to initiatives and consortia involving the National Institutes of Health, National Science Foundation, and industry partners including Genentech and Amgen to translate lab-scale demonstrations into scalable processes. Her career trajectory included service on scientific advisory boards and participation in translational programs sponsored by organizations like DARPA and Bill & Melinda Gates Foundation.

Synthetic biology and RNA-based systems

Smolke is notable for developing RNA-based gene-control devices and genetically encoded sensors that enable complex information processing in cells, leveraging concepts from CRISPR-Cas9 research, riboswitch design, and synthetic regulatory circuits. Her laboratory engineered RNA scaffolds, ligand-responsive aptamers, and catalytic RNA devices to control gene expression and metabolic flux in eukaryotic hosts such as Saccharomyces cerevisiae and mammalian cell lines used by groups at Cold Spring Harbor Laboratory and Whitehead Institute. She led projects to assemble multi-enzyme pathways for the biosynthesis of alkaloids and opioids, intersecting with biochemical pathways characterized by researchers at Scripps Research and Max Planck Institute for Terrestrial Microbiology. Her publications connect to broader efforts in programmable therapeutics pursued by teams at Stanley Center for Psychiatric Research and process optimization research at Novartis and Pfizer.

Entrepreneurship and commercialization

Translational outcomes from Smolke’s research include founding and advising startups aimed at producing valuable natural products via fermentation, building on commercial precedents set by companies such as Amyris, Ginkgo Bioworks, and Zymergen. She engaged with technology transfer offices from Stanford University and investor networks including Y Combinator, Kleiner Perkins, and Sequoia Capital to shepherd intellectual property into venture-backed ventures and licensing agreements. Her entrepreneurial activities involved partnerships with contract development and manufacturing organizations in the biotech sector, aligning with commercialization strategies used by Biogen and Regeneron to scale biologics and small-molecule production. Smolke has also contributed to policy and ethics discussions with stakeholders from World Health Organization and national advisory panels on responsible innovation in synthetic biology.

Awards and honors

Smolke’s recognition includes prizes and fellowships from agencies and organizations that support excellence in biotechnology and engineering, comparable to awards given by the National Science Foundation, Hewlett Foundation, and professional societies such as the American Association for the Advancement of Science and the Institute of Electrical and Electronics Engineers for interdisciplinary impact. She has been invited to deliver named lectures at universities including Harvard University, Yale University, and University of Cambridge, and served on panels for grant review with the National Institutes of Health and evaluation committees for international scientific prizes like those administered by the Royal Society.

Category:Living people Category:Synthetic biologists Category:Biotechnologists